Ernesto Calderon Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ernesto Calderon Martinez has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alan C. Braverman
Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO
2 shared publications - Anji T. Yetman
University of Nebraska Medical Center
2 shared publications - Dianna M. Milewicz
University of Texas Health Science Center at Houston
2 shared publications - Julie De Backer
Ghent University Hospital
2 shared publications - Richmond W. Jeremy
Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
2 shared publications - Shaine Alaine Morris
Division of Pediatric Cardiology, Department of Pediatrics Texas Children's Hospital and Baylor College of Medicine Houston Texas USA
2 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (1) , e005169
ACTA2 Pathogenic Variants Activating Heat Shock Factor 1 and Increasing Cholesterol Biosynthesis in Smooth Muscle Cells Predispose to Early Onset Atherosclerosis
BACKGROUND: ACTA2 pathogenic variants predispose to thoracic aortic disease, and a subset of variants lead to early onset atherosclerotic cardiovascular disease (ASCVD). The molecular pathway linking misfolded SMA (α-smooth muscle actin) monomers to augmented atherosclerosis–associated smooth muscle cell phenotypic modulation can be modeled in vitro by stably expressing the ACTA2 p.R149C variant in Acta2 −/− smooth muscle cells. METHODS: The Montalcino Aortic Consortium patient registry was used to identify cases with ACTA2 pathogenic/likely pathogenic missense variants. These patients were surveyed, and medical records were reviewed, to identify cases with early onset ASCVD. The variants for these cases, as well as other recurrent ACTA2 missense variants, were individually expressed in Acta2 −/− smooth muscle cells, and transcript and protein levels, HSF1 (heat shock factor 1) activation, HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) expression and activity, cholesteryl ester levels, and downstream smooth muscle cell phenotypic modulation were assessed. RESULTS: Early onset ASCVD included coronary artery disease, peripheral vascular disease, and atherosclerotic plaques identified by imaging in the arch, descending, or abdominal aorta, along with the celiac, iliac, renal, or vertebral arteries. Twelve ACTA2 variants were identified to be associated with early onset ASCVD. Early onset ASCVD was correlated with HSF1 activation ( P =0.035), cellular cholesteryl ester levels ( P =0.0031), and having one family member with the specific ACTA2 pathogenic variant who had early onset ASCVD ( P =0.0001). CONCLUSIONS: Assays assessing the molecular mechanism that leads to early onset ASCVD can identify which ACTA2 pathogenic variants will trigger this condition. Ultimately, this information informs precision medical care for individuals with ACTA2 pathogenic variants, with the ultimate goal of preventing thoracic aortic disease and ASCVD.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (1) , e005169
Open AccessACTA2 Pathogenic Variants Activating Heat Shock Factor 1 and Increasing Cholesterol Biosynthesis in Smooth Muscle Cells Predispose to Early Onset Atherosclerosis
BACKGROUND: ACTA2 pathogenic variants predispose to thoracic aortic disease, and a subset of variants lead to early onset atherosclerotic cardiovascular disease (ASCVD). The molecular pathway linking misfolded SMA (α-smooth muscle actin) monomers to augmented atherosclerosis–associated smooth muscle cell phenotypic modulation can be modeled in vitro by stably expressing the ACTA2 p.R149C variant in Acta2 −/− smooth muscle cells. METHODS: The Montalcino Aortic Consortium patient registry was used to identify cases with ACTA2 pathogenic/likely pathogenic missense variants. These patients were surveyed, and medical records were reviewed, to identify cases with early onset ASCVD. The variants for these cases, as well as other recurrent ACTA2 missense variants, were individually expressed in Acta2 −/− smooth muscle cells, and transcript and protein levels, HSF1 (heat shock factor 1) activation, HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) expression and activity, cholesteryl ester levels, and downstream smooth muscle cell phenotypic modulation were assessed. RESULTS: Early onset ASCVD included coronary artery disease, peripheral vascular disease, and atherosclerotic plaques identified by imaging in the arch, descending, or abdominal aorta, along with the celiac, iliac, renal, or vertebral arteries. Twelve ACTA2 variants were identified to be associated with early onset ASCVD. Early onset ASCVD was correlated with HSF1 activation ( P =0.035), cellular cholesteryl ester levels ( P =0.0031), and having one family member with the specific ACTA2 pathogenic variant who had early onset ASCVD ( P =0.0001). CONCLUSIONS: Assays assessing the molecular mechanism that leads to early onset ASCVD can identify which ACTA2 pathogenic variants will trigger this condition. Ultimately, this information informs precision medical care for individuals with ACTA2 pathogenic variants, with the ultimate goal of preventing thoracic aortic disease and ASCVD.
- Open Access
Bicuspid Aortic Valve in Heritable Thoracic Aortic Disease: Insights from the Montalcino Aortic Consortium
Bicuspid aortic valve (BAV) is the most common congenital heart malformation and predisposes to thoracic aortic aneurysms. The Montalcino Aortic Consortium (MAC) registry collects genetic and phenotypic data on individuals with heritable thoracic aortic disease genes (HTAD PVs) that primarily regulate smooth muscle cell contraction or TGF-β signaling (TGF-β PVs, termed Loeys-Dietz Syndrome (LDS)). We evaluated associations between BAV, HTAD PVs and aortic outcomes in the MAC cohort. BAV was present in 48 (6%) of 816 MAC participants (age 38 [IQR 20-52] years, 51% female) and was not significantly increased in males or in the entire TGF-β PV group (417 with TGF-β PVs, p=0.14) but was enriched in participants with TGFBR1 or TGFBR2 PVs (16/168, 10% vs. 32/648, 5%, PR 1.93 [1.08, 3.43], pP< 0.001), younger age at first aortic event (24 vs. 40 years, p0.5). Sinus of Valsalva dilation (Z>3, 25/48, 52% vs. 128/768, 17%, P< 0.0001) and ascending aorta dilation (Z>3, 12/48, 25% vs. 26/768, 3%, P< 0.0001) were more common in participants with BAV. Participants with both TGF-β PV and BAV more frequently had aortic valve surgery (17/30, 57% vs. 110/387, 28%, PR 1.99 [1.40-2.83], pLDS TGFBR1 and TGFBR2 , and is associated with accelerated aortic valve and aortic diseasebut does not confer an increased risk for aortic dissection. These observations highlight the potential benefits of genetic testing for BAV patients who have a family history of HTAD, a sinus of Valsalva aneurysm, or clinical features suggestive of LDS.
Open AccessBicuspid Aortic Valve in Heritable Thoracic Aortic Disease: Insights from the Montalcino Aortic Consortium
Bicuspid aortic valve (BAV) is the most common congenital heart malformation and predisposes to thoracic aortic aneurysms. The Montalcino Aortic Consortium (MAC) registry collects genetic and phenotypic data on individuals with heritable thoracic aortic disease genes (HTAD PVs) that primarily regulate smooth muscle cell contraction or TGF-β signaling (TGF-β PVs, termed Loeys-Dietz Syndrome (LDS)). We evaluated associations between BAV, HTAD PVs and aortic outcomes in the MAC cohort. BAV was present in 48 (6%) of 816 MAC participants (age 38 [IQR 20-52] years, 51% female) and was not significantly increased in males or in the entire TGF-β PV group (417 with TGF-β PVs, p=0.14) but was enriched in participants with TGFBR1 or TGFBR2 PVs (16/168, 10% vs. 32/648, 5%, PR 1.93 [1.08, 3.43], pP< 0.001), younger age at first aortic event (24 vs. 40 years, p0.5). Sinus of Valsalva dilation (Z>3, 25/48, 52% vs. 128/768, 17%, P< 0.0001) and ascending aorta dilation (Z>3, 12/48, 25% vs. 26/768, 3%, P< 0.0001) were more common in participants with BAV. Participants with both TGF-β PV and BAV more frequently had aortic valve surgery (17/30, 57% vs. 110/387, 28%, PR 1.99 [1.40-2.83], pLDS TGFBR1 and TGFBR2 , and is associated with accelerated aortic valve and aortic diseasebut does not confer an increased risk for aortic dissection. These observations highlight the potential benefits of genetic testing for BAV patients who have a family history of HTAD, a sinus of Valsalva aneurysm, or clinical features suggestive of LDS.